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Abstract
Background: A number of studies indicate that taurine promotes cholesterol conversion to bile acids by
upregulating CYP7A1 gene expression. Few in vitro studies are concerned the concentration change of cholesterol
and its product of bile acids, and the molecular mechanism of CYP7A1 induction by taurine.
Methods: The levels of intracellular total cholesterol (TC), free cholesterol (FC), cholesterol ester (EC), total bile acids
(TBA) and medium TBA were determined after HepG2 cells were cultured for 24/48 h in DMEM supplemented with
taurine at the final concentrations of 1/10/20 mM respectively. The protein expressions of CYP7A1, MEK1/2, c-Jun,
p-c-Jun and HNF-4α were detected.
Results: Taurine significantly reduced cellular TC and FC in dose —and time-dependent ways, and obviously
increased intracellular/medium TBA and CYP7A1 expressions. There was no change in c-Jun expression, but the protein
expressions of MEK1/2 and p-c-Jun were increased at 24 h and inhibited at 48 h by 20 mM taurine while HNF4α was
induced after both of the 24 h and 48 h treatment.
Conclusion: Taurine could enhance CYP7A1 expression by inducing HNF4α and inhibiting MEK1/2 and p-c-Jun
expressions to promote intracellular cholesterol metabolism.
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Background
Taurine (2-aminoethanesulfonic acid) is a sulfur-containing
amino acid mainly obtained through diet in humans as only
small amounts can be synthesized endogenously [1]. A
great number of studies have revealed that taurine has
cholesterol-lowering effect since Tsuji et al. published their
experimental data in 1979 [2–4]. Furthermore, many
studies indicate that the cholesterol-lowering effect of
taurine is due to the increased biotransformation of choles-
terol to bile acids in the liver and the subsequent excretion
of bile acids in feces [5–7].
Cholesterol conversion or bile acids biosynthesis is
critically regulated in order to maintain cholesterol or
bile acids homeostasis in the body. Cholesterol 7α-hy-
droxylase (CYP7A1), the rate-limiting enzyme in the
major bile acids synthetic pathway, is widely reported to
be regulated by several nuclear receptors at the level of
gene transcription [8–10]. It has been confirmed that
liver X receptor-α (LXRα) is considered as a positive
regulator of CYP7A1 transcription, and hepatocyte nu-
clear factor 4α (HNF4α) and liver receptor homolog-1
(LRH-1) are essential factors for basal level expression of
CYP7A1 [11, 12]. It has also been pointed out that there
are two pathways to feedback repress CYP7A1 transcrip-
tion, one being the bile acids receptor—farnesoid X recep-
tor (FXR)-dependent which interacts with HNF4α and
LRH-1 via atypical nuclear receptor small heterodimer
partner-1 (SHP-1) induced by FXR, and the other being the
FXR-independent pathway which involves many factors
such as the tumor necrosis factor (TNF) receptor, the
mitogen-activated protein kinase/c-Jun N-terminal kinase
(MAPK/JNK), the mitogen-activated protein kinase/extra-
cellular signal regulated kinase (MAPK/ERK, MEK) signal
transduction etc. [13–15].
Many studies on the hypercholesterolemia rat and
mouse have revealed that taurine increases the mRNA
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expression and activity of CYP7A1 [5, 6, 16, 17], and
the same improvement has also been observed via the
in vitro experiment [7]. The in vitro studies have fo-
cused on the upregulating-effect of taurine on
CYP7A1 mRNA level, but the regulatory mechanism
and the changes of cellular bile acids, the products of
cholesterol degradation, have not been discussed.
Moreover, the molecular mechanism of CYP7A1 in-
duction by taurine has rarely been discussed although
the regulatory pathway of CYP7A1 and its relative
nuclear receptors or factors have been studied exten-
sively. In 2006, Lam et al. reported that taurine
almost did not alter the mRNA levels of LXRα, LRH-
1, FXR and SHP-1 of mice with high cholesterol or
cholesterol/sodium cholate diets, although CYP7A1
mRNA level was significantly decreased by choles-
terol/sodium cholate diet and then two-fold increased
by taurine supplementation [18]. Their results
suggested that FXR was indeed activated by choles-
terol/sodium cholate diet and then functioned as a
down-regulator to CYP7A1 in spite of no change of
mRNA level, and that taurine might stimulate
CYP7A1 expression not by repressing FXR-dependent
pathway but by FXR-independent pathway.
In the present study, HepG2 cell line derived from
human hepatoma cell was used to investigate the
dose- and time-dependent effects of taurine with a
focus on the change of CYP7A1 expression and the
concentration of cholesterol and bile acids. In
addition, the expressions of several important factors
involved in FXR-independent pathway such as MEK1/
2, phosphorylated c-Jun (p-c-Jun) and HNF4α etc.
were determined to discuss the preliminary molecular
mechanism of CYP7A1 induction by taurine.
Methods
Reagents
The cell culture reagents were obtained from Hyclone
(Logan, USA) and the fetal bovine serum (FBS) was
obtained from Gibco (New York, USA). The taurine,
cholesterol, cholesterol esterase, cholesterol oxidase,
horseradish peroxidase and sodium taurocholate
hydrate were purchased from Sigma (St. Louis, MO,
USA). The PowerOpti-ECL Western blotting detection
reagent was purchased from GenView (Florida, USA).
The primary (anti-CYP7A1, sc-25536; anti-c-jun,
sc-1694; anti-p-c-jun, sc-7980-R; and anti–HNF4α,
sc-8987) and secondary (anti-rabbit immunoglobulin
G, sc-2004) antibodies were acquired from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The primary
anti-MEK1/2 antibody (D1A5) was obtained from Cell
Signaling Technology (Beverly, MA, USA). The
primary anti-β-actin antibody was obtained from
GenView (Florida, USA). The BCA Protein Assay Kit,
Cell Lysis Buffer and PMSF were purchased from
Beyotime (Nanjing, Jiangsu, China). All the other
chemicals were purchased from Dingguo Changsheng
Biotechnology Co. Ltd (Beijing, China).
Cell culture and treatment
The HepG2 cell line obtained from Cell Resource Center
(School of Basic Medicine Peking Union Medical
College) were routinely cultured in DMEM supple-
mented with 10% heat-inactivated fetal calf serum,
2 mM L-glutamine, 100U/ml penicillin and 100ug/ml
streptomycin. The cells were grown in the 75 mm2-
culture flasks at 37 °C in a humidified atmosphere of
95% air and 5% CO2 before treatment. For the experi-
ment, the cells were plated out in 6-well plates and incu-
bated in media containing taurine (0, 1, 10 and 20 mM)
for 24 h or 48 h. The cells with 0 mM taurine treatment
were taken as control and were given PBS instead of
taurine. Each treatment was carried out at least in triplicate.
The results of our preliminary experiments showed
that about 90% of the cells survived in the medium
with final concentration of 20 mM taurine, while less
than 70% survived with 30 mM. Thus, 20 mM taurine
was determined as the largest concentration in
present experiments.
Cellular cholesterol quantification
The intracellular cholesterol was determined by the
description of Omodeo with few modifications [19].
Briefly, after being washed for 3 times with cold PBS,
the cells were treated with 1 mL hexane/isopropanol
(2:1, v:v) for 30 min at room temperature. The organic
solvent was transferred to the test tubes, then the wells
were washed with an additional 1 mL hexane/isopropa-
nol, and the washing solutions were also transferred to
the corresponding test tubes. The organic solvent was
removed under nitrogen, and the lipids were resus-
pended in 130 μL isopropanol with 10% TritonX-100.
The cellular total cholesterol (TC) and free cholesterol
(FC) content were measured as follows: 50 μL of the
lipid samples was treated with TC or FC working
solution shown in Table 1 for 30 min at 37 °C and op-
tical density was determinate at 500 nm using a μQuant
microplate spectrophotometers (Bio-Tek instruments
INC, USA). The cellular ester cholesterol (EC) was
calculated by TC minus FC.
After the cell lipids were extracted by the organic
solvent, the remainders were lysed in Cell Lysis Buffer
and then the protein concentration was determined by
the BCA Protein Assay Kit.
Intracellular and medium bile acids quantification
The HepG2 cells and their medium were separately col-
lected. The cells were lysed with PBS containing 2%
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Triton X-100 for 45 min and supernatant were obtained
by centrifugation at 10,000 rpm for 10 min. Then the
total bile acids (TBA) in the supernatant and in the
medium were quantified respectively by using enzyme
colorimetric method by TBA kit (Nanjing Jiancheng
technologies Co., China) following the manufacturer’s
instructions. The cellular protein concentration was also
determined by BCA Protein Assay Kit.
Immunoblotting assay
The HepG2 cells were lysed in ice-cold lysis buffer contain-
ing 10 mM Tris–HCl (pH 7.4), 0.1 M EDTA, 10 mM NaCl,
0.5% Triton X-100 and PMSF. The homogenates were
clarified by centrifugation at 12,000 rpm for 10 min at 4 °C,
and the protein concentration was determined by the BCA
Protein Assay Kit. The samples with the same amount of
protein were boiled in the sample buffer (5% β-
mercaptoethanol) for 5 min, and then were separated by
SDS-PAGE and blotted onto a PVDF membrane (Millipore,
USA). After the nonspecific protein binding was blocked by
incubation in PBS containing 5% nonfat dry milk, the
membranes were incubated with the primary antibodies
overnight at 4 °C which were diluted in the blocking buffer
as follows: anti-CYP7A1, 1:1000; anti-c-jun, 1:800;
anti-p-c-jun, 1:1000; anti-MEK1/2, 1:2000; anti-HNF4α,
1:800. Subsequently the membranes were incubated with
1:2000 dilutions of secondary antibody for 1 h, and immu-
noreactive bands were detected by using an ECL western
blot detection reagent and exposed to the chemilumines-
cence film of high performance for 1 ~ 5 min. Finally, the
immunoblots were scanned and quantified by using a Gel
imaging system (GE healthcare, USA).
Statistical analysis
All the data were expressed as the mean ± standard
error, and the statistical analysis was performed by one-
way ANOVA. The differences were considered to be
statistically significant at p < 0.05.
Results
Taurine reduced cellular cholesterol and increased bile
acids
The in vivo experiments have confirmed that taurine
significantly decreases the serum and liver cholesterol levels
and increases the fecal bile acids excretion [4, 5, 16, 17]. In
the present in vitro experiment HepG2 cells were incubated
with taurine for 24 h or 48 h and the changes of TC, FC,
EC and TBA were determined.
As shown in Table 2, taurine significantly reduced the
cellular TC, FC and EC after the 24 h or 48 h culture,
and the decreases of TC and FC were apparently dose-
and time-dependent with taurine. Table 3 shows that the
intracellular TBA levels increased by taurine in a dose-
dependent way after 24 h incubation, while the TBA
concentration in medium also distinctly enhanced but
reached the peak at 10 mM taurine treatment. This
implied that time was needed for the excretion of the
intracellular TBA synthesized from cholesterol to the
culture medium. After the culture for 48 h, the intracel-
lular TBA increased marginally and reached a peak at
10 mM taurine whereas the medium TBA improved in a
dose-dependent way. Additionally, both of the intracellu-
lar and the medium TBA levels were further increased
by 1 mM taurine comparison with that of 24 h-incuba-
tion. This suggested that 48 h of culture seemed to be
the time required for the intracellular TBA production
and its excretion into the medium. All the above results
indicated that 20 mM taurine most effectively reduced
the intracellular cholesterol and increased the intracellu-
lar and medium bile acids after 48 h treatment.
Taurine induced CYP7A1 protein expression
The dose- and time-relationship between taurine and the
CYP7A1 protein expression in HepG2 cells were analyzed
by immunoblotting, and β-actin was used as the endogen-
ous control. Figure 1 A/B showed that CYP7A1 protein
levels significantly increased in a dose-dependent way
Table 2 The effect of taurine on cellular cholesterol level
(μg/mg · pro)
Control Taurine
1 mM 10 mM 20 mM
Culture for 24 h (n = 5)
TC 150.9 ± 7.7 140.8 ± 6.3 134.8 ± 5.3* 127.3 ± 5.9*
FC 105.2 ± 7.0 99.2 ± 6.0 93.5 ± 5.3* 86.9 ± 6.2*
EC 45.6 ± 3.1 41.6 ± 3.8 41.3 ± 2.3 40.4 ± 2.3*
Culture for 48 h (n = 6)
TC 153.8 ± 2.7 132.7 ± 3.6* 119.6 ± 3.7* 112.1 ± 4.6*
FC 111.0 ± 4.8 98.3 ± 5.8* 85.3 ± 3.6* 72.5 ± 4.5*
EC 42.8 ± 4.4 34.4 ± 5.1* 34.3 ± 6.4* 39.5 ± 5.1
*Compared with control, P < 0.05
Table 1 Composition of working solutions for cholesterol
detection
Chemicals TC (μL) FC (μL)
Dipotassium hydrogen phosphate (0.1 M) 192 198
Cholesterol oxidase (5U/mL) 6 6
Horse radish peroxidase (50U/mL) 6 6
Sodium taurocholate hydrate (20 mM) 15 15
TritonX-100(1%) 15 15
4-aminoantipyrine (5.5 mM) 45 45
Phenol (280 mM) 15 15
Cholesterol esterase (25U/mL) 6 0
Total volume (μL) 300 300
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after 24 h taurine treatment. Figure 1 C/D showed
CYP7A1 protein levels of HepG2 cells treated with
20 mM taurine for 12 h, 24 h and 48 h. The results
demonstrated that CYP7A1 expression improved and
reached a peak on 24 h, and the level of 48 h still
significantly increased compared with that of the con-
trol and 12 h.
Taurine affected several key factors associated with
CYP7A1 expression
Several key moleculars involved in the FXR-independent
pathway of CYP7A1 regulation were measured. Figure 2
A/B and C/D showed that the protein expression of
MEK1/2 and p-c-jun in HepG2 cells were promoted at
24 h and inhibited at 48 h by 20 mM taurine treatment.
This suggested that the synthesized bile acids activated
MEK1/2 and phosphorylated c-Jun in the early period of
cholesterol degradation, and subsequently taurine
suppressed MEK1/2 and p-c-Jun expression with
prolonged incubating time. Figure 2 E/F indicated that
the full-length expression of HNF4α with 54 kDa
molecular weight was dramatically induced at both 24 h
and 48 h since it has been reported to be essential for
CYP7A1 expression, and the truncated HNF-4α N-
terminal with 40 kDa molecular weight was also signifi-
cantly increased accompanying the increase of full
length HNF4α by taurine treatment although it was less
in control. All the above results indicated that taurine
may increase CYP7A1 expression by promoting HNF4α
and repressing MEK1/2 and p-c-Jun.
Discussions
Cholesterol conversion to bile acids in the liver plays a
vital role for the elimination of cholesterol, which is one
of the main factors regulating cholesterol homeostasis in
the body. The first and rate-limiting reaction in the
major bile acid synthetic pathway is the 7α-hydroxylation
of cholesterol, which is catalyzed by CYP7A1 [20, 21].
Many in vivo studies with hypercholesterolemia rat,
mouse and hamster reveal that the cholesterol-lowering
effect of taurine is carried out by enhancing CYP7A1
activity or gene expression and fecal bile acid excre-
tion [5, 6, 16, 17], while in vitro researches are few.
Yanagita T et al. noted that the cellular cholesterol
levels decreased and synthesis of cholesterol ester was
inhibited when the HepG2 cells were incubated in
DMEM medium with taurine for 24 h [22]. Lam NV
et al. reported that taurine significantly increased
CYP7A1 mRNA level and promoted cholesterol
degradation regardless of whether the HepG2 cells
were cultured under the conditions of high choles-
terol or not [7], and Hoang HM et al. indicated that
CYP7A1 mRNA levels increased 3 times when the
Table 3 The effect of taurine on intracellular and medium TBA
levels
Control Taurine
1 mM 10 mM 20 mM
culture for 24 h (n = 5)
Intracellular
(μmol/g · pro)
1.05 ± 0.06 1.83 ± 0.07* 2.32 ± 0.05* 2.88 ± 0.11*
Medium (μmol/L) 0.67 ± 0.07 1.37 ± 0.07* 2.72 ± 0.03* 2.27 ± 0.09*
culture for 48 h (n = 6)
Intracellular
(μmol/g · pro)
1.55 ± 0.03 3.24 ± 0.07* 3.46 ± 0.07* 3.03 ± 0.04*
Medium (μmol/L) 1.28 ± 0.03 1.95 ± 0.07* 2.34 ± 0.03* 2.47 ± 0.02*
*Compared with control, P < 0.05
Fig. 1 Effect of taurine on CYP7A1 protein expression in HepG2 cells. a and b, HepG2 cells were treated with taurine (1, 10, 20 mM) for 24 h (n = 6),
showed that CYP7A1 protein levels significantly increased in a dose-dependent way after 24 h taurine treatment. c and d, HepG2 cells were treated in
20 mM taurine for 12 h, 24 h and 48 h (n = 3), showed CYP7A1 expression improved and reached a peak at 24 h, and the level of 48 h still significantly
increased compared with that of control and 12 h. *P < 0.05 compared with control or corresponding group
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H4IIE cells were treated with taurine [23]. The above
in vitro studies focused on the effect of taurine on
CYP7A1 mRNA level, and the changes of cellular bile
acids, the products of cholesterol degradation, were
not discussed.
In the present study, the CYP7A1 expression, cellu-
lar cholesterol and bile acids were determined in
order to comprehensively discuss the effect of taurine
on cholesterol metabolism. The results of dose- and
time-relationship between taurine and CYP7A1 pro-
tein expression showed that CYP7A1 expression
significantly increased in a positive dose-dependent
way after 24 h treatment, and reached a peak at 24 h
when the cell was cultured with 20 mM taurine for
12/24/48 h. The results of cholesterol and bile acids
showed that taurine significantly reduced cellular TC
and FC in dose- and time-dependent manner,
increased intracellular TBA level in dose-dependent
way after 24 h treatment and enhanced the medium
TBA in dose-dependent way after 48 h culture. More-
over, both of the intracellular and medium TBA levels
of 48 h culture were further improved by 1 mM
taurine compared with that of the 24 h culture. This
suggested that 48 h of culture seemed to be the time
needed for the intracellular TBA production and its
excretion into medium. All the above results indicate
that taurine can enhance CYP7A1 expression and
subsequently promote intracellular cholesterol catab-
olism, and the decrease of cholesterol is associated
with taurine concentration and action duration, show-
ing a superior cholesterol lowering effect at 48 h to
that at 24 h.
It has been clear that several nuclear receptors play
key roles in CYP7A1 regulation to maintain cholesterol/
bile acid homeostasis. HNF-4α, an orphan member of
the nuclear receptor superfamily, is an important regula-
tor of CYP7A1 gene expression as demonstrated by in
vitro promoter analysis and by characterization of mice
with a liver-specific deficiency of HNF-4α or LRH-1 de-
ficiency [24, 25]. The clinical study showed the
expression of HNF4α was significantly increased in
human liver biopsies from patients treated with chole-
styramine in parallel with markedly increased expression
of CYP7A1, indicating that HNF4α may also regulate
the expression of CYP7A1 in humans [26]. Therefore,
HNF4α expression was investigated in the present study,
and the data showed that it was induced by taurine after
both of the 24 h and 48 h treatment, suggesting that the
Fig. 2 Effect of taurine on several key factors associated with CYP7A1 expression in HepG2 cells. HepG2 cells were incubated with 20 mM taurine
for 24 h and 48 h. Fig a, b and c, d respectively showed the protein expressions of MEK1/2 and p-c-jun in HepG2 cells were promoted at 24 h
and inhibited at 48 h by 20 mM taurine treatment. Fig e, f showed that HNF4α was dramatically induced at both of 24 h and 48 h. The values
represent the mean ± SE (n = 3). *P < 0.05 compared with the control and other corresponding group
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increase of HNF4α protein level results in an induction
of CYP7A1 expression and bile acids synthesis.
It has also been pointed out that there are two path-
ways to feedback repress CYP7A1 transcription, one
being FXR-dependent which interacts with HNF4α and
LRH-1 via atypical nuclear receptor SHP-1 induced by
FXR, and the other being FXR-independent pathway
which involves many factors such as TNF receptor,
MAPK/JNK signal transduction, etc. [13–15]. Studies
not only suggested that TNFα inhibit HNF4α trans-
activating activity and CYP7A1 gene transcription via
the MAPK/ERK (MEK) signaling pathway, but also
showed that bile acids can activate the c-Jun N-terminal
kinase (JNK)/c-Jun pathway to phosphorylate c-Jun
which combines with HNF4α to inhibit the CYP7A1
gene [14, 27, 28]. Furthermore, Lam et al. reported that
taurine did not alter the mRNA levels of FXR and
SHP-1 of mice with high cholesterol diet although the
CYP7A1 mRNA level was significantly increased [18],
and Das J. indicated that taurine can decrease JNK activ-
ity by repressing the phosphorylation of PKCδ in
NaAsO2 exposure rat’s liver [29]. Therefore, MEK1/2,
c-Jun and p-c-Jun expression were investigated in the
present study. The data showed there was no apparent
change in c-Jun expression, but the protein expression
of MEK1/2 and p-c-jun were increased at 24 h and
inhibited at 48 h by 20 mM taurine. This suggested that
the synthesized bile acids activated MEK1/2 and
phosphorylated c-Jun in the early period of cholesterol
degradation, and subsequently taurine suppressed
MEK1/2 and p-c-Jun expression with prolonged treat-
ment time, and finally relieved the inhibition of bile acid
to CYP7A1 gene expression.
Conclusion
In conclusion, the present study shows that taurine
promotes the bioconversion of cholesterol to bile
acids in the HepG2 cell, and the decrease of choles-
terol or the increase of bile acids is associated with
taurine concentration and action duration, showing a
superior effect at 48 h to that at 24 h. The results in
our study indicate that taurine could enhance
CYP7A1 expression by inducing HNF4α and inhibit-
ing MEK1/2 and p-c-Jun to accelerate intracellular
cholesterol metabolism. Further experiments need to
be done to understand the detailed signaling pathways
of CYP7A1 up-regulation by taurine.
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